Publications by authors named "Sudhir Manda"

Claim this Profile
F
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.
Barry Paul, Jiri Minarik, Francesca Cottini, Cristina Gasparetto, Jack Khouri, Sudhir Manda

EJHaem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter, Sudhir Manda

Haematologica· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Sudhir Manda, Bertrand M Anz, Christopher Benton, E Randolph Broun, Habte A Yimer

Hematol Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati, Sudhir Manda

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke, Sudhir Manda

Lancet Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Sudhir Manda, Habte A Yimer, Stephen J Noga, Saulius Girnius, Christopher A Yasenchak

Clin Lymphoma Myeloma Leuk· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
Max J Gordon, Michael Churnetski, Hamood Alqahtani, Xavier Rivera, Adam Kittai, Sudhir Manda

Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Sudhir Manda, Nancy Dunbar, Cynthia R Marx-Wood, Alexey V Danilov

Br J Haematol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cocaine-induced thrombotic vasculopathy.
Seby John, Sudhir Manda, David Hamrock

Am J Med Sci· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal evolution of patient characteristics enrolled on phase I trials.
Afshin Dowlati, Madappa Kundranda, Sudhir Manda, Lauren Patrick, Pingfu Fu

Invest New Drugs· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors.
Charles J Nock, Joanna M Brell, Joseph A Bokar, Matthew M Cooney, Brenda Cooper, Sudhir Manda

Invest New Drugs· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-institutional phase I trials of anticancer agents.
Afshin Dowlati, Sudhir Manda, Joseph Gibbons, Scot C Remick, Lauren Patrick

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis